

References

- Dieterich DT, and Spivak JL (2002).** Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis; 185:S128-S137.
- Elhajj II, Sharara AI, Taher AT, et al (2004).** Chronic hepatitis C associated with Coombs-positive hemolytic anemia. Hematol J.; 5:364-6.
- Fried MW, Shiffman ML, Reddy KR, et al (2002).** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med. ;347:975-82.
- Gaeta GB, Precone DF, Felaco FM et al(2002).**, Premature discontinuation of interferon plus ribavirin for adverse effects: A multicentre survey in real world patients with chronic hepatitis C. Aliment Pharmacol Ther.; 16:1633-9.
- Hung C-H, Lee C-M, Lu S-N, et al; (2006).** Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors and impact on treatment response. Liver International: 26: 1079-1086.
- Manns MP, Mc Hutchison JG, Gorgon SC, et al; (2007).** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet.; 358:958-65.
- Peck-Radosavljevic M, Wichtas M, Homoncik Kraml M, et al; (2002).** Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology; 123:141-51.
- Seeff LB (2002).** Natural history of chronic hepatitis C. Hepatology ;36:S30-S34.
- Van Vlierbergh H, Delange JR, et al; (2008).** Factors influencing ribavirin-induced hemolysis. J Hepatol. :34:911-6.